CDTX Share Price Performance
US$221.38
152.67 (222.19%)
121.4% overvalued intrinsic discount
US$100.00
Fair Value
Price US$221.38
birdflustocks US$100.00
AnalystConsensusTarget US$221.50
Fair ValueUS$100.00
Share Pricen/a
New Narrative • Mar 05
Cidara Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 44 Fair Values set on narratives written by author
CDTX Community Narratives
BI
Fair Value
·Fair Value US$100 121.4% overvalued intrinsic discount
Cidara Therapeutics: The underestimated potential of CD388
9users have liked this narrative
0users have commented on this narrative
35users have followed this narrative
AN
Fair Value
·Fair Value US$221.5 Fairly Valued intrinsic discount
Expanded Phase III Trial And BARDA Support Will Shape Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Cidara Therapeutics
121.4% overvalued intrinsic discount
Cidara Therapeutics: The underestimated potential of CD388
View narrativeBI
Published 11 Jan 2025
Cidara Therapeutics
Fairly Valued intrinsic discount
Expanded Phase III Trial And BARDA Support Will Shape Long Term Outlook
View narrativeAN
Published 5 Mar
Trending Discussion
No trending discussion available.
Recently Updated Narratives
BI
Cidara Therapeutics: The underestimated potential of CD388
Fair Value: US$100 121.4% overvalued intrinsic discount
35 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Expanded Phase III Trial And BARDA Support Will Shape Long Term Outlook
Fair Value: US$221.5 Fairly Valued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cidara Therapeutics, Inc. Key Details
About CDTX
- Founded
- 2012
- Employees
- 38
- CEO
- WebsiteView website
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
